Chardan analyst Geulah Livshits initiated coverage of 4D Molecular with a Buy rating and $30 price target. 4D’s platform comprises synthetic AAVs selected by screening large libraries in non-human primates models for evasion of existing neutralizing antibodies and efficient delivery to target tissues using clinically relevant routes of administration, the analyst tells investors in a research note. The firm says the company’s platform has the potential to tackle historic obstacles to in vivo gene delivery.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FDMT:
- FDMT Soars on Positive Interim Data in Cystic Fibrosis Lung Disease
- 4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting
- 4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
- 4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting
